Drug intelligence / Profile preview

ova323-339 vaccine

Development stage: Preclinical
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intranasal, Intraperitoneal, Subcutaneous

Overview

OVA323-339 vaccine refers to a research-grade peptide-based agent derived from the ovalbumin (OVA) protein, specifically spanning amino acid residues 323 to 339 (sequence: ISQAVHAAHAEINEAGR). This peptide represents a major antigenic and allergenic epitope that binds to the I-A(d) MHC class II molecule, making it a critical tool for studying CD4+ T-cell activation and class II MHC-peptide interactions. In preclinical research, it is extensively used in murine models to induce and study hypersensitivity responses, such as allergic airway inflammation and asthma. It is primarily supplied by research reagent companies for laboratory use and is not intended for human clinical applications.

Other names: Ovalbumin (323-339)OVA (323-339) peptideISQAVHAAHAEINEAGR

Targets

I-A^d (Mouse major histocompatibility complex class II i-ad)OVA-specific TCR (Ovalbumin-specific T-cell receptor)

Beyond the preview

Go deeper on ova323-339 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ova323-339 vaccine.

Explore the full profile